The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The immune landscape in Hepatitis Delta Virus Infection - still an open field!
Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13785. Online ahead of print.
1Barts Liver Centre, Blizard Institute, Barts and The London, School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.
Abstract
Hepatitis delta virus (HDV) is known to cause the most aggressive and severe form of viral hepatitis, yet it remaind under-diagnosed, but does require early diagnosis for accurate disease staging. Antibody to HDV (anti-HDV) is the primary screening tool and should be assessed in patients with hepatitis B surface antigen (HBsAg) positivity, as HDV is a satellite RNA virus of hepatitis B. Additionally, the viral load (HDV RNA) should be assessed in those with positive anti-HDV, to differentiate between active infection and resolved hepatitis delta. Data regarding immune responses in HDV are limited, but show dysfunctional adaptive and innate immunity. Many studies however fail to distinguish between active and resolved infection. Limited treatments are available for HDV, but promise has been shown with the newly approved Bulevirtide, a first-in-class HBV entry-inhibitor. Thus immune response during therapy require further investigsation, alongwith additional targets for HDV cure.